CJC-1295 with DAC features a Drug Affinity Complex that extends its half-life by binding to albumin, resulting in sustained GHRH receptor activation for prolonged GH research studies.
| Molecular Weight | 3647.0 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH). The DAC modification allows the peptide to bind to albumin in the blood, extending its life from minutes to over a week.
CJC-1295 DAC works by providing a constant signal to the pituitary gland to release Growth Hormone. Unlike the "pulsatile" release seen with non-DAC versions, the DAC version creates a sustained elevation of GH and IGF-1 levels, mimicking a steady-state hormonal environment.
Because of its long half-life, CJC-1295 DAC is a favorite for long-term research into tissue repair, muscle growth, and metabolic optimization. It is studied for its ability to improve protein synthesis, enhance fat loss, and support systemic recovery in chronic injury models.